The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.
SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback